Fleischer L, Kirchhoff H, Schoenherr C, Heidenreich O, Scherr M, Eder M. Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia. Haematologica; https://doi.org/10.3324/haematol.2026.300519 [Early view].